Afficher la notice abrégée

dc.creatorLima M., Aloizou A.-M., Siokas V., Bakirtzis C., Liampas I., Tsouris Z., Bogdanos D.P., Baloyannis S.J., Dardiotis E.en
dc.date.accessioned2023-01-31T08:55:11Z
dc.date.available2023-01-31T08:55:11Z
dc.date.issued2022
dc.identifier10.1515/revneuro-2021-0148
dc.identifier.issn03341763
dc.identifier.urihttp://hdl.handle.net/11615/75928
dc.description.abstractThe purpose of this review is to examine whether there is a possible (etiological/triggering) relationship between infection with various Coronaviruses, including Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2), the virus responsible for the Coronavirus disease-19 (Covid-19) pandemia, and Multiple Sclerosis (MS), and whether an increase of the prevalence of MS after the current Covid-19 pandemia should be expected, examining new and preexisting data. Although the exact pathogenesis of MS remains unknown, environmental agents seem to greatly influence the onset of the disease, with viruses being the most popular candidate. Existing data support this possible etiological relationship between viruses and MS, and experimental studies show that Coronaviruses can actually induce an MS-like demyelinating disease in animal models. Findings in MS patients could also be compatible with this coronaviral MS hypothesis. More importantly, current data from the Covid-19 pandemia show that SARS-CoV-2 can trigger autoimmunity and possibly induce autoimmune diseases, in the Central Nervous System as well, strengthening the viral hypothesis of MS. If we accept that Coronaviruses can induce MS, it is reasonable to expect an increase in the prevalence of MS after the Covid-19 pandemia. This knowledge is of great importance in order to protect the aging groups that are more vulnerable against autoimmune diseases and MS specifically, and to establish proper vaccination and health policies. © 2022 Maria Lima et al., published by De Gruyter, Berlin/Boston.en
dc.language.isoenen
dc.sourceReviews in the Neurosciencesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85126528185&doi=10.1515%2frevneuro-2021-0148&partnerID=40&md5=e2a16caf52971baff6ae06d1914e57b4
dc.subjectautoantibodyen
dc.subjectepitopeen
dc.subjectSARS-CoV-2 vaccineen
dc.subjectsuperantigenen
dc.subjectagingen
dc.subjectantibody blood levelen
dc.subjectArticleen
dc.subjectautoimmune disease of the central nervous systemen
dc.subjectautoimmunityen
dc.subjectbrain tissueen
dc.subjectbystander effect (cell)en
dc.subjectcerebrospinal fluid analysisen
dc.subjectCoronavirinaeen
dc.subjectcoronavirus disease 2019en
dc.subjectdata analysisen
dc.subjectdemyelinating diseaseen
dc.subjectdemyelinationen
dc.subjectdisease activityen
dc.subjectdisease associationen
dc.subjectdisease courseen
dc.subjectdisease modelen
dc.subjectdisease risk assessmenten
dc.subjectenvironmental factoren
dc.subjectevidence based medicineen
dc.subjectexperimental studyen
dc.subjecthealth care policyen
dc.subjecthumanen
dc.subjecthypothesisen
dc.subjectleukocyte counten
dc.subjectmultiple sclerosisen
dc.subjectnonhumanen
dc.subjectpandemicen
dc.subjectpathophysiologyen
dc.subjectprevalenceen
dc.subjectprophylaxisen
dc.subjectrisk factoren
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjectvaccinationen
dc.subjectvulnerable populationen
dc.subjectanimalen
dc.subjectmultiple sclerosisen
dc.subjectpandemicen
dc.subjectprevalenceen
dc.subjectAnimalsen
dc.subjectCOVID-19en
dc.subjectHumansen
dc.subjectMultiple Sclerosisen
dc.subjectPandemicsen
dc.subjectPrevalenceen
dc.subjectSARS-CoV-2en
dc.subjectDe Gruyter Open Ltden
dc.titleCoronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia?en
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée